P
Promontory Therapeutics
Clinical-stage company developing novel small molecule immunogenic anti-cancer agents with a focus on oncology therapeutics
About Promontory Therapeutics
Promontory Therapeutics is a private, clinical-stage drug development company specializing in oncology therapeutics. The company is dedicated to advancing novel small molecule immunogenic anti-cancer agents. Its lead drug candidate, PT 112, is a highly potent immunogenic cell death (ICD) inducer currently in Phase 2 clinical development. PT 112 has demonstrated single-agent activity and safety, and it shows synergy with immune checkpoint inhibitors. Promontory Therapeutics operates multiple clinical trials across the United States and Europe, aiming to lead the development of immunogenic small molecules in cancer care. The company collaborates with outstanding institutions and partners to further its mission. Promontory Therapeutics generates revenue through partnerships, licensing agreements, and potential future sales of its drug candidates.
Source: Dealroom company dataNews
Open roles
Promontory Therapeutics in the New York City ecosystem
The Promontory Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- AAAdinvest AG
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Promontory Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Promontory Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

